Drug disposition: To phenotype or genotype

International Journal of Pharmaceutical Medicine

Volumn 15, Issue 2, 2001, Pages 70-73

  Maurice, Dickins ^a   Geoff, Tucker ^a  

^a INCONNU ^*

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOCHROME P450 2D6; DRUG; DRUG METABOLIZING ENZYME; GENE PRODUCT;

ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSPORT; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0035011217     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124363-200104000-00008     Document Type: Article

References (51)

1. Pharmacogenetics
2. Pharmacogenetics and adverse drug reactions
3. Pharmacogenetics and future drug development and delivery
4. Genetic key to personal medicines
5. The promise of precision prescriptions
6. Clinical implications of genetic polymorphism in drug metabolism
7. Advances in drug metabolism and its contribution to variability in patient response
8. Concentration- or effect-controlled clinical trials with sparse data
9. Pharmacogenomics: Translating functional genomics into rational therapies
10. CYP2C9 lle359 and Leu359 variants: Enzyme kinetic study with seven substrates
11. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
12. Alprazolam - Ritonavir interaction: Implications for product labelling
13. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
14. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
15. Identification of functionally important MDR1 variant alleles among African-American and Caucasian subjects
16. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
17. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug - Drug interaction
18. Pharmacokinetic interaction of digoxin with a herbal extract from St John's wort (Hypericum perforatum)
19. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
20. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
21. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
22. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
23. Polymorphism of the cytochrome P450 2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
24. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population
25. Elucidation of the common genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
26. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
27. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
28. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes
29. Determination of drug-metabolizing enzyme activity in vivo: Pharmacokinetic and statistical issues
30. In vivo indices of enzyme activity: The effect of renal impairment on the assessment of CYP2D6 activity
31. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates
32. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
33. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions
34. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence
35. Influence of oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects
36. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
37. Drug extrapyramidal side-effects or not: Is there a dextromethorphan phenotype difference?
38. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer disease
39. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
40. Cytochrome P450 polymorphisms are associated with reduced warfarin dose
41. Influence of oxidation polymorphism on phenformin kinetics and dynamics
42. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype
43. Impact of environmental and genetic factors on codeine analgesia
44. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine
45. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
46. The antitussive effect of dextromethorphan in relation to CYP2D6 activity
47. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
48. Pharmacogenetic testing in the clinic and cost comparisons
49. Testing drug response in the presence of genetic information: Sampling issues for clinical trials
50. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
51. Will genetics revolutionize medicine?